Cambrian Bio is a clinical-stage drug development company focused on creating therapeutics that target the biological mechanisms of aging to prevent chronic diseases. By collaborating with leading scientists, Cambrian aims to develop effective and safe therapies that extend healthspan and improve patient outcomes.
Funding
$203.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic diseases are associated with the biological mechanisms of aging, yet therapeutic development often focuses on treating individual diseases rather than addressing the underlying aging processes. This approach may limit the potential for preventing or delaying the onset of multiple age-related conditions simultaneously.
Solution
Cambrian Bio is a clinical-stage drug development company focused on creating therapeutics that target the fundamental biological mechanisms of aging. By partnering with scientists and leveraging advancements in aging biology, Cambrian aims to develop therapies that can prevent or treat multiple chronic diseases associated with aging. Their approach seeks to extend healthspan and improve patient outcomes by addressing the root causes of age-related decline.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related chronic diseases, as well as healthcare providers seeking innovative approaches to prevent and treat these conditions.
Features
- Focus on therapeutics targeting the biological mechanisms of aging
- Partnerships with scientists to advance research and development
- Development of therapies to treat and prevent chronic diseases
- Aims to extend healthspan and improve patient outcomes